PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 9, 2026Reports — Medical Cases Images and VideosOpen Access

Outcomes of Lurbinectedin in Central Nervous System Metastases of Small Cell Lung Cancer: A Single-Institution Retrospective Case Series

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNavanita BiswasCSCarolin SchmidtSRShoja Rahimian

Discussion

Loading...

Member takes

Overview

Retrospective case series evaluates intracranial outcomes of lurbinectedin in small cell lung cancer with CNS metastases, indicating limited efficacy.

Key Points

  • This study aims to evaluate the intracranial efficacy of lurbinectedin in patients with small cell lung cancer (SCLC) and CNS metastases.
  • Conducted a single-institution retrospective case series among patients with confirmed SCLC and radiologic CNS metastases treated with lurbinectedin.
  • Evaluated CNS disease control rate (CNS-DCR) and intracranial progression-free survival (iPFS) as primary endpoints.
  • Analyzed outcomes of 30 treated patients, of whom 14 had CNS metastases at any time.
  • Among patients with baseline CNS disease, one patient (20%) achieved CNS disease control, corresponding to radiographic improvement.
  • Median intracranial progression-free survival (iPFS) was approximately 2.5 months for the cohort.
  • No CNS-specific adverse events related to lurbinectedin treatment were reported.

Cite This Study

Biswas et al. (2026) studied this question.

synapsesocial.com/papers/6a27add2a963992e16267f80https://doi.org/10.3390/reports9020179
View Full Paper
Ask AI
Bookmark
Share